



### BiCNU<sup>®</sup> (carmustine) – First-time generic

- On September 13, 2018, Zydus Pharmaceuticals launched Navinta's [AP-rated](#) generic version of [BiCNU \(carmustine\)](#) 100 mg injection.
- BiCNU is indicated as palliative therapy as a single agent or in established combination therapy in the following:
  - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors
  - Multiple myeloma in combination with [prednisone](#)
  - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs
  - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.
- BiCNU carries a boxed warning for myelosuppression and pulmonary toxicity.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.